Press release

Twist Bioscience to Highlight Genotyping by Sequencing and Methylation Solution During AGBT

Sponsored by Businesswire

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced several events at the virtual 2021 Advances in Genome Biology and Technology (AGBT) meeting to be held March 1-3, 2021.

During the conference, Twist will host a workshop with customer presentations from Regeneron Genetics Center and HelioHealth; Twist will present a poster detailing the ongoing development of its Artificial Barcoded Libraries; and, will have a virtual booth. The events are listed below:

Date: March 1, 2:45pm – 3:10pm EST

“Believe in Better – an update from Twist” — Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience

“No more arrays: genotyping by sequencing enables economical and improved association studies” Gonçalo Abecasis, D.Phil, Vice President, Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center

“NGS Methylation in Cancer Detection” — Kenneth Chahine, Ph.D., J.D., CEO, HelioHealth

Date: Tuesday, March 2, 3:30pm-5:30pm EST

Poster Session

Abstract: Increasing the throughput of NGS sequencing through rational design and empirical validation of 10,000 Unique Dual Indexes (UDI). To assess the performance of individual barcodes to increase the throughput of NGS sequencing, Twist developed Artificial Barcoded Libraries (ABLs), a high throughput NGS library generation method that utilizes fragmentation of a human genomic source and automation to generate thousands of unique NGS libraries with minimal bias. The approach yielded more than 10,000 pairs of 12bp UDI primers. Performance criteria for uniform UDI primer sets with thousands of members that are suitable for high multiplex hybridization applications and investigations are presented.

Presenter: Richard Gantt, Twist Bioscience

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on February 9, 2021 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.